These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624 [TBL] [Abstract][Full Text] [Related]
11. Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study. Chen G; McIver CM; Texler M; Lloyd JM; Rieger N; Hewett PJ; Sen Wan D; Hardingham JE Dis Colon Rectum; 2004 May; 47(5):679-86. PubMed ID: 15037935 [TBL] [Abstract][Full Text] [Related]
12. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Schulz S; Hyslop T; Haaf J; Bonaccorso C; Nielsen K; Witek ME; Birbe R; Palazzo J; Weinberg D; Waldman SA Clin Cancer Res; 2006 Aug; 12(15):4545-52. PubMed ID: 16899600 [TBL] [Abstract][Full Text] [Related]
13. Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Carlson MR Mol Diagn Ther; 2009; 13(1):11-4. PubMed ID: 19351210 [TBL] [Abstract][Full Text] [Related]
14. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA J Surg Oncol; 2012 Jul; 106(1):24-30. PubMed ID: 22252429 [TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Conzelmann M; Dieterle CP; Linnemann U; Berger MR Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701 [TBL] [Abstract][Full Text] [Related]
16. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684 [TBL] [Abstract][Full Text] [Related]
18. Does stage II colorectal cancer need to be redefined? Grothey A Clin Cancer Res; 2011 May; 17(10):3053-5. PubMed ID: 21498396 [TBL] [Abstract][Full Text] [Related]
19. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Waldman SA; Cagir B; Rakinic J; Fry RD; Goldstein SD; Isenberg G; Barber M; Biswas S; Minimo C; Palazzo J; Park PK; Weinberg D Dis Colon Rectum; 1998 Mar; 41(3):310-5. PubMed ID: 9514425 [TBL] [Abstract][Full Text] [Related]
20. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Frick GS; Pitari GM; Weinberg DS; Hyslop T; Schulz S; Waldman SA Expert Rev Mol Diagn; 2005 Sep; 5(5):701-13. PubMed ID: 16149873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]